IL33 and benign prostatic hyperplasia: explore IL-33 expression in PCa using bioinformatics analyses (TCGA, TIMER, HPA databases), followed by validation in clinical samples (PCa, benign prostatic hyperplasia [BPH], and non-cancerous tissues) (14).